Claims for Patent: 10,287,351

Summary for Patent: 10,287,351

Title:	Compositions and methods to enhance the immune system
Abstract:	The invention relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g. cancer cells or virus-infected cells, by the host\'s immune system. Provided is a composition comprising (i) a therapeutic compound that can trigger a host\'s immune effector cells against an aberrant cell, such as a therapeutic antibody, and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPalpha.
Inventor(s):	Van Den Berg; Timo Kars (Amsterdam, NL)
Assignee:	Stichting Sanquin Bloedvoorziening (Amsterdam, NL)
Application Number:	15/618,837
Patent Claims:	1. A method of enhancing in vivo efficacy of a therapeutic antibody to induce cancer cell destruction by antibody-dependent cellular cytotoxicity (ADCC) in a human subject receiving anti-cancer treatment with a therapeutic antibody comprising a human or non-human primate IgG Fc portion, wherein the therapeutic antibody induces ADCC, said method comprising administering to said subject prior to, simultaneously, or after the administration of the therapeutic antibody, an agent capable of reducing or preventing inhibitory signal transduction initiated via SIRP.alpha., wherein the agent is in an amount sufficient to increase ADCC such that the in vivo efficacy of the therapeutic antibody to induce cancer cell destruction by ADCC is enhanced, and wherein said agent is an anti-CD47 antibody, a Fab fragment thereof, or a F(ab')2 fragment thereof. 2. The method according to claim 1, wherein the anti-cancer treatment is directed against non-Hodgkin's lymphoma, breast cancer, chronic lymphocytic leukemia, lung cancer, or colorectal cancer. 3. The method according to claim 1, wherein the therapeutic antibody is selected from the group consisting of rituximab, trastuzumab, alemtuzumab, bevacizumab, cetuximab, and panitumumab. 4. The method according to claim 1, wherein the therapeutic antibody is rituximab. 5. The method according to claim 4, wherein the anti-cancer treatment is directed against non-Hodgkin's lymphoma or chronic lymphocytic leukemia. 6. The method according to claim 4, wherein the agent capable of reducing or preventing inhibitory signal transduction initiated via SIRP.alpha. is an anti-CD47 antibody. 7. The method according to claim 1, wherein the therapeutic antibody is trastuzumab. 8. The method according to claim 7, wherein the anti-cancer treatment is directed against breast cancer. 9. The method according to claim 1, wherein the therapeutic antibody is cetuximab. 10. The method according to claim 9, wherein the anti-cancer treatment is directed against colorectal cancer. 11. The method according to claim 9, wherein the agent capable of reducing or preventing inhibitory signal transduction initiated via SIRP.alpha. is an anti-CD47 antibody. 12. The method according to claim 1, wherein the anti-CD47 antibody, Fab fragment thereof, or F(ab')2 fragment thereof is administered to said subject prior to the administration of the therapeutic antibody or wherein the anti-CD47 antibody, Fab fragment thereof, or F(ab')2 fragment thereof is administered to said subject after the administration of the therapeutic antibody. 13. The method according to claim 1, wherein the anti-CD47 antibody, Fab fragment thereof, or F(ab')2 fragment thereof and the therapeutic antibody are administered simultaneously. 14. The method according to claim 1, wherein the therapeutic antibody comprises a human IgG1 Fc portion or a human IgG3 Fc portion. 15. A method of treating cancer in a subject receiving anti-cancer treatment with a therapeutic antibody selected from the group consisting of rituximab, trastuzumab, alemtuzumab, bevacizumab, cetuximab, and panitumumab, said method comprising administering to said human subject prior to, simultaneously, or after the administration of the therapeutic antibody, an anti-CD47 antibody, a Fab fragment thereof, or a F(ab')2 fragment thereof. 16. The method according to claim 15, wherein the therapeutic antibody is rituximab. 17. The method according to claim 16, wherein the anti-cancer treatment is directed against non-Hodgkin's lymphoma or chronic lymphocytic leukemia. 18. The method according to claim 16, wherein the agent capable of reducing or preventing inhibitory signal transduction initiated via SIRP.alpha. is an anti-CD47 antibody. 19. The method according to claim 15, wherein the therapeutic antibody is trastuzumab. 20. The method according to claim 19, wherein the anti-cancer treatment is directed against breast cancer. 21. The method according to claim 15, wherein the therapeutic antibody is alemtuzumab. 22. The method according to claim 21, wherein the anti-cancer treatment is directed against chronic lymphocytic leukemia. 23. The method according to claim 15, wherein the therapeutic antibody is cetuximab. 24. The method according to claim 23, wherein the anti-cancer treatment is directed against colorectal cancer. 25. The method according to claim 23, wherein the agent capable of reducing or preventing inhibitory signal transduction initiated via SIRP.alpha. is an anti-CD47 antibody. 26. The method according to claim 15, wherein the anti-cancer treatment is directed against non-Hodgkin's lymphoma, breast cancer, chronic lymphocytic leukemia, lung cancer, or colorectal cancer. 27. The method according to claim 15, wherein the anti-CD47 antibody, Fab fragment thereof, or F(ab')2 fragment thereof is administered to said subject prior to the administration of the therapeutic antibody or after administration of the therapeutic antibody. 28. The method according to claim 15, wherein the anti-CD47 antibody, Fab fragment thereof, or F(ab')2 fragment thereof and the therapeutic antibody are administered simultaneously. 29. The method according to claim 15, wherein the therapeutic antibody comprises a human IgG1 Fc portion. 30. A composition comprising (i) a therapeutic antibody comprising a human or non-human primate IgG Fc portion, wherein the therapeutic antibody is capable of inducing cancer cell destruction by antibody-dependent cellular cytotoxicity (ADCC), and (ii) an agent capable of reducing or preventing inhibitory signal transduction initiated via SIRP.alpha., wherein said agent is an anti-CD47 antibody, a Fab fragment thereof, or a F(ab')2 fragment thereof.

Details for Patent 10,287,351

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2028-04-23
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2028-04-23
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2028-04-23